Benitec Biopharma Inc. (BNTC) Stock Analysis & Investment Frameworks
Benitec Biopharma Inc. (BNTC) stock analysis on Invetso. Review Benitec Biopharma Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Benitec Biopharma Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Benitec Biopharma Inc. Key Financial Metrics
- Market Cap: $332.84M
- Revenue: $N/A
- ROE: -28.41%
- ROIC: -28.80%
- Dividend Yield: N/A
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.